Provided by Tiger Fintech (Singapore) Pte. Ltd.

Editas Medicine

1.03
-0.0900-8.04%
Post-market: 1.080.0481+4.67%19:57 EDT
Volume:3.13M
Turnover:3.33M
Market Cap:85.47M
PE:-0.36
High:1.15
Open:1.11
Low:1.02
Close:1.12
Loading ...

Why Is Editas (EDIT) Down 37.1% Since Last Earnings Report?

Zacks
·
04 Apr

Dyne Therapeutics Names Erick Lucera as CFO

MT Newswires Live
·
21 Mar

Dyne Therapeutics Names Editas Medicine's Lucera as CFO

Dow Jones
·
21 Mar

BRIEF-Editas Medicine Announces Chief Financial Officer Transition

Reuters
·
21 Mar

Editas Medicine CFO Erick Lucera to step down, Amy Parison to succeed

TIPRANKS
·
21 Mar

Editas Medicine Announces Chief Financial Officer Transition

THOMSON REUTERS
·
21 Mar

Editas Medicine Inc - Amy Parison Appointed as Editas CFO

THOMSON REUTERS
·
21 Mar

Press Release: Editas Medicine Announces Chief Financial Officer Transition

Dow Jones
·
21 Mar

Cautious Hold Rating on Editas Medicine Amid Early Development Stage and Long-Term Milestones

TIPRANKS
·
15 Mar

Here's Why Editas Medicine (NASDAQ:EDIT) Must Use Its Cash Wisely

Simply Wall St.
·
13 Mar

Is Lithia Motors Inc. (NYSE:LAD) Among the Most Promising Car Stocks According to Hedge Funds?

Insider Monkey
·
12 Mar

Buy Rating for Editas Medicine Driven by Promising Preclinical Advances and Strong Financial Position

TIPRANKS
·
07 Mar

Editas Medicine Inc.’s Stock Volatility: Key Risks and Investor Considerations

TIPRANKS
·
07 Mar

Analysts’ Top Healthcare Picks: Editas Medicine (EDIT), Viking Therapeutics (VKTX)

TIPRANKS
·
07 Mar

Editas Q4 Loss Wider Than Expected, Revenues Fall Y/Y, Stock Down

Zacks
·
06 Mar

Barclays Keeps Their Hold Rating on Editas Medicine (EDIT)

TIPRANKS
·
06 Mar

Editas Medicine: Balancing Financial Stability and Strategic Uncertainties with a Hold Rating

TIPRANKS
·
06 Mar

Editas Medicine Reports Progress in Gene Editing

TIPRANKS
·
06 Mar

Editas Medicine Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
06 Mar

Editas Medicine (EDIT) Reports Q4 Loss, Misses Revenue Estimates

Zacks
·
06 Mar